RASSF1A hypermethylation is associated with ASXL1 mutation and indicates an adverse outcome in non-M3 acute myeloid leukemia

References

• FerraraFSchifferCAAcute myeloid leukaemia in adultsLancet2013381986548449523399072
   PubMed Web of Science ®Google Scholar
• LevineRLMolecular pathogenesis of AML: translating insights to the clinicBest Pract Res Clin Haematol201326324524824309525
   PubMed Web of Science ®Google Scholar
• KhaledSAl MalkiMMarcucciGAcute myeloid leukemia: biologic, prognostic and therapeutic insightsOncology (Williston Park)201630431832927085330
   PubMed Web of Science ®Google Scholar
• JabbourECortesJRavandiFO’BrienSKantarjianHTargeted therapies in hematology and their impact on patient care: chronic and acute myeloid leukemiaSemin Hematol201350427128324246694
   PubMed Web of Science ®Google Scholar
• PastoreFLevineRLEpigenetic regulators and their impact on therapy in acute myeloid leukemiaHaematologica2016101326927826928248
   PubMed Web of Science ®Google Scholar
• Conway O’BrienEPrideauxSChevassutTThe epigenetic landscape of acute myeloid leukemiaAdv Hematol2014201410317524778653
   PubMedGoogle Scholar
• HennessyBTGarcia-ManeroGKantarjianHMGilesFJDNA methylation in haematological malignancies: the role of decitabineExpert Opin Investig Drugs2003121219851993
   PubMed Web of Science ®Google Scholar
• SchoofsTMüller-TidowCDNA methylation as a pathogenic event and as a therapeutic target in AMLCancer Treat Rev201137Suppl 1S13S1821612874
   PubMed Web of Science ®Google Scholar
• LiMGaoLLiZCTNNA1 hypermethylation, a frequent event in acute myeloid leukemia, is independently associated with an adverse outcomeOncotarget2016721314543146527129146
   PubMedGoogle Scholar
• GaoLLiuFZhangHSunJMaYCHFR hypermethylation, a frequent event in acute myeloid leukemia, is independently associated with an adverse outcomeGenes Chromosomes Cancer201655215816826542416
   PubMed Web of Science ®Google Scholar
• LiYGaoLLuoXEpigenetic silencing of microRNA-193a contributes to leukemogenesis in t(8;21) acute myeloid leukemia by activating the PTEN/PI3K signal pathwayBlood2013121349950923223432
   PubMed Web of Science ®Google Scholar
• van der WeydenLAdamsDJThe Ras-association domain family (RASSF) members and their role in human tumourigenesisBiochim Biophys Acta200717761588517692468
   PubMed Web of Science ®Google Scholar
• DonningerHVosMDClarkGJThe RASSF1A tumor suppressorJ Cell Sci2007120Pt 183163317217878233
   PubMed Web of Science ®Google Scholar
• HessonLBCooperWNLatifFThe role of RASSF1A methylation in cancerDis Markers2007231–2738717325427
   PubMedGoogle Scholar
• SimonsAShafferLGHastingsRJCytogenetic nomenclature: changes in the ISCN 2013 compared to the 2009 editionCytogenet Genome Res201314111623817294
   PubMed Web of Science ®Google Scholar
• SlovakMLKopeckyKJCassilethPAKaryotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group StudyBlood200096134075408311110676
   PubMed Web of Science ®Google Scholar
• LiuFGaoLJingYDetection and clinical significance of gene rearrangements in Chinese patients with adult acute lymphoblastic leukemiaLeuk Lymphoma20135471521152623210573
   PubMed Web of Science ®Google Scholar
• ShenYZhuYMFanXGene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemiaBlood2011118205593560321881046
   PubMed Web of Science ®Google Scholar
• GuanLGaoLWangLThe frequency and clinical significance of IDH1 mutations in Chinese acute myeloid leukemia patientsPLoS One2013812e8333424376688
   PubMedGoogle Scholar
• ChenTCHouHAChouWCDynamics of ASXL1 mutation and other associated genetic alterations during disease progression in patients with primary myelodysplastic syndromeBlood Cancer J201441e17724442206
   PubMedGoogle Scholar
• HaferlachTNagataYGrossmannVLandscape of genetic lesions in 944 patients with myelodysplastic syndromesLeukemia201428224124724220272
   PubMed Web of Science ®Google Scholar
• ItzyksonRKosmiderORennevilleAPrognostic score including gene mutations in chronic myelomonocytic leukemiaJ Clin Oncol201331192428243623690417
   PubMed Web of Science ®Google Scholar
• YangJSchifferCAGenetic biomarkers in acute myeloid leukemia: will the promise of improving treatment outcomes be realized?Expert Rev Hematol20125439540722992234
   PubMed Web of Science ®Google Scholar
• MuratiABrecquevilleMDevillierRMozziconacciMJGelsi-BoyerVBirnbaumDMyeloid malignancies: mutations, models and managementBMC Cancer20121230422823977
   PubMed Web of Science ®Google Scholar
• ShihAHAbdel-WahabOPatelJPLevineRLThe role of mutations in epigenetic regulators in myeloid malignanciesNat Rev Cancer201212959961222898539
   PubMed Web of Science ®Google Scholar
• JasielecJSalouraVGodleyLAThe mechanistic role of DNA methylation in myeloid leukemogenesisLeukemia20142891765177324913729
   PubMed Web of Science ®Google Scholar
• SmithBDBeachCLMahmoudDWeberLHenkHJSurvival and hospitalization among patients with acute myeloid leukemia treated with azacitidine or decitabine in a large managed care population: a real-world, retrospective, claims-based, comparative analysisExp Hematol Oncol2014311024666795
   PubMedGoogle Scholar
• YunSVinceletteNDAbrahamIRobertsonKDFernandez-ZapicoMEPatnaikMMTargeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trialsClin Epigenetics201686827307795
   PubMed Web of Science ®Google Scholar
• DingKFuRLiuHNachnaniDAShaoZHEffects of decitabine on megakaryocyte maturation in patients with myelodysplastic syndromesOncol Lett20161142347235227073478
   PubMedGoogle Scholar
• GriffithsEAGoreSDHookerCAcute myeloid leukemia is characterized by Wnt pathway inhibitor promoter hypermethylationLeuk Lymphoma20105191711171920795789
   PubMed Web of Science ®Google Scholar
• JohanMFBowenDTFrewMEGoodeveACReillyJTAberrant methylation of the negative regulators RASSFIA, SHP-1 and SOCS-1 in myelodysplastic syndromes and acute myeloid leukaemiaBr J Haematol20051291606515801956
   PubMed Web of Science ®Google Scholar
• AvramouliATsochasSMandalaEMethylation status of RASSF1A in patients with chronic myeloid leukemiaLeuk Res20093381130113219193434
   PubMedGoogle Scholar
• PaschkaPSchlenkRFGaidzikVIASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian Acute Myeloid Leukemia Study GroupHaematologica2015100332433025596267
   PubMed Web of Science ®Google Scholar
• ShivarovVGueorguievaRIvanovaMTiuRVASXL1 mutations define a subgroup of patients with acute myeloid leukemia with distinct gene expression profile and poor prognosis: a meta-analysis of 3311 adult patients with acute myeloid leukemiaLeuk Lymphoma20155661881188325308295
   PubMed Web of Science ®Google Scholar
• SchnittgerSEderCJerominSASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcomeLeukemia2013271829123018865
   PubMed Web of Science ®Google Scholar
• OdenikeOThirmanMJArtzASGodleyLALarsonRAStockWGene mutations, epigenetic dysregulation, and personalized therapy in myeloid neoplasia: are we there yet?Semin Oncol201138219621421421110
   PubMedGoogle Scholar
• TakahashiSCurrent findings for recurring mutations in acute myeloid leukemiaJ Hematol Oncol201143621917154
   PubMed Web of Science ®Google Scholar
• GillHLeungAYKwongYLMolecular targeted therapy in acute myeloid leukemiaFuture Oncol201612682783826828965
   PubMedGoogle Scholar